Early Alzheimer's drug trial progress briefing outlining the study's status. Useful preview for investors and researchers curious about next steps.
Key Takeaways
- Trial enrolled 850 patients confirmed positive for pTau217 blood biomarker
- Participants were randomized in a placebo-controlled, double-blind study across 83 US clinical sites
- Two pre-specified readouts will analyze six-month symptomatic and 18-month disease-modifying effects